FACTS 001 QA 2.9.14_MB MS LC KA.docx.docx

First Page		Document Content
Date: 2015-02-24 14:32:35 Health Sexually transmitted diseases and infections HIV/AIDS Herpes CAPRISA 004 Gilead Sciences Tenofovir HIV Microbicides for sexually transmitted diseases Medicine Microbiology Microbicides		FACTS 001 QA 2.9.14_MB MS LC KA.docx.docx Add to Reading List Source URL: www.usaid.gov Download Document from Source Website File Size: 573,10 KB Share Document on Facebook

	Press Release: MayOmololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to a Pioneering Community Educator Who Brings the Voices of Community Members and Participants t DocID: 1gbaX - View Document
	FACTS 001 QA 2.9.14_MB MS LC KA.docx.docx DocID: 1fD6y - View Document
	Using Antiretrovirals to Prevent HIV: Implications of the outcome of the CAPRISA 004 tenofovir-gel microbicide trial SAVE THE DATE: Tuesday, 20 July 2010, 6.30pm-8.30pm An official satellite of XVII International AIDS Co DocID: 1deAN - View Document
	Results of the CAPRISA 004 trial of tenofovir gel Salim S Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director: CAPRISA DocID: 1ci9M - View Document
	What is CAPRISA 004? CAPRISA 004 was a phase IIb, two-arm, double-blind, randomised, placebo-controlled trial designed to assess the safety and effectiveness of the vaginal microbicide candidate 1% tenofovir gel for the DocID: 1bY73 - View Document